
Quintiles appoints Tom Pike as new chief executive
pharmafile | April 24, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Quintiles, Tom Pike, biopharmaceutical
Quintiles, the biopharmaceutical services company, has appointed Tom Pike as its new chief executive, effective from 30 April.
The appointment is part of the company’s long-term succession planning. Denis Gilling CBE, who founded the company, steps down as it chief executive, but will continue as executive chairman of its board of directors.
Pike brings 30 years of experience to Quintiles, spanning a variety of industries and leading companies.
He spent 22 years at Accenture, including more than 10 years in leadership roles. At Accenture, Pike’s roles included leading the North America health and products business areas.
Prior to that, he was the global chief operating officer for Accenture’s resources operating group and had also served as the company’s chief strategy officer.
Since leaving Accenture in 2010, Pike has been involved with a number of start-ups in the technology and healthcare sectors.
Related Content

ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models
Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced …

Biopharmaceutical company EQRx set to be acquired by Revolution Medicines
On 1 August 2023, Revolution Medicines signed an official agreement confirming the acquisition of the …

Quintiles to merge with IMS Health
IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement …






